ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 1,029.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,236 shares of the biotechnology company's stock after purchasing an additional 35,763 shares during the period. Tower Research Capital LLC TRC's holdings in ADMA Biologics were worth $673,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. MetLife Investment Management LLC grew its stake in ADMA Biologics by 4.7% in the 4th quarter. MetLife Investment Management LLC now owns 136,212 shares of the biotechnology company's stock worth $2,336,000 after acquiring an additional 6,060 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in ADMA Biologics in the 4th quarter worth approximately $1,888,000. Dimensional Fund Advisors LP grew its stake in ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after acquiring an additional 643,661 shares during the period. Altium Capital Management LLC grew its stake in ADMA Biologics by 2.6% in the 4th quarter. Altium Capital Management LLC now owns 1,395,000 shares of the biotechnology company's stock worth $23,924,000 after acquiring an additional 35,000 shares during the period. Finally, Jump Financial LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $403,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 2.2 %

Shares of NASDAQ ADMA traded down $0.53 during trading on Thursday, hitting $23.27. 2,782,071 shares of the company traded hands, compared to its average volume of 3,685,790. ADMA Biologics, Inc. has a 1 year low of $6.52 and a 1 year high of $25.67. The company has a 50-day moving average price of $19.29 and a 200-day moving average price of $18.40. The firm has a market capitalization of $5.53 billion, a P/E ratio of 83.11 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.